

Carmel Mary Hawley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3062130/publications.pdf>

Version: 2024-02-01

262
papers

11,592
citations

19657

61
h-index

43889

91
g-index

267
all docs

267
docs citations

267
times ranked

9863
citing authors

#	ARTICLE	IF	CITATIONS
1	Representativeness of the PDOPPS cohort compared to the Australian PD population. <i>Peritoneal Dialysis International</i> , 2022, 42, 403-414.	2.3	2
2	Multiple Cerebral Aneurysms in an Adult With Autosomal Recessive Polycystic Kidney Disease. <i>Kidney International Reports</i> , 2021, 6, 219-223.	0.8	8
3	Utility of serum beta-trace protein as a tool for estimating residual kidney function in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2021, 41, 226-235.	2.3	1
4	Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD. <i>Kidney International Reports</i> , 2021, 6, 1032-1040.	0.8	0
5	Kidney Transplant Outcomes in elderly Recipients: An Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry Study. <i>Transplantation Proceedings</i> , 2021, 53, 1915-1926.	0.6	5
6	Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1365-1375.	4.5	10
7	Novel trial strategies to enhance the relevance, efficiency, effectiveness, and impact of nephrology research. <i>Kidney International</i> , 2020, 98, 572-578.	5.2	5
8	Effect of patient- and center-level characteristics on uptake of home dialysis in Australia and New Zealand: a multicenter registry analysis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1938-1949.	0.7	14
9	Multicentre registry data analysis comparing outcomes of culture-negative peritonitis and different subtypes of culture-positive peritonitis in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2020, 40, 47-56.	2.3	24
10	Impending challenges of the burden of end-stage kidney disease in Australia. <i>Medical Journal of Australia</i> , 2019, 211, 374.	1.7	10
11	Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol. <i>BMJ Open</i> , 2019, 9, e023736.	1.9	8
12	Health data linkage research in Australia remains challenging. <i>Internal Medicine Journal</i> , 2019, 49, 539-544.	0.8	27
13	NAV-KIDS2 trial: protocol for a multi-centre, staggered randomised controlled trial of a patient navigator intervention in children with chronic kidney disease. <i>BMC Nephrology</i> , 2019, 20, 134.	1.8	14
14	Chronic Kidney Disease and Pulse Wave Velocity: A Narrative Review. <i>International Journal of Hypertension</i> , 2019, 2019, 1-11.	1.3	44
15	Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the Impact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study. <i>BMJ Open</i> , 2019, 9, e024382.	1.9	18
16	Report of the Standardized Outcomes in Nephrology Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure for Hemodialysis Vascular Access. <i>American Journal of Kidney Diseases</i> , 2018, 71, 690-700.	1.9	62
17	Association between causes of peritoneal dialysis technique failure and all-cause mortality. <i>Scientific Reports</i> , 2018, 8, 3980.	3.3	32
18	Outcomes of <i>Acinetobacter</i> Peritonitis in Peritoneal Dialysis Patients: A Multicenter Registry Analysis. <i>Peritoneal Dialysis International</i> , 2018, 38, 257-265.	2.3	12

#	ARTICLE	IF	CITATIONS
19	Risk Predictors and Causes of Technique Failure Within the First Year of Peritoneal Dialysis: An Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Study. <i>American Journal of Kidney Diseases</i> , 2018, 72, 188-197.	1.9	85
20	Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry. <i>American Journal of Kidney Diseases</i> , 2018, 71, 814-821.	1.9	66
21	Establishing a Core Outcome Measure for Fatigue in Patients on Hemodialysis: A Standardized Outcomes in Nephrologyâ€“Hemodialysis (SONG-HD) Consensus Workshop Report. <i>American Journal of Kidney Diseases</i> , 2018, 72, 104-112.	1.9	69
22	Impact of Diabetes Mellitus on the Association of Vascular Disease Before Transplantation With Long-term Transplant and Patient Outcomes After Kidney Transplantation: A Population Cohort Study. <i>American Journal of Kidney Diseases</i> , 2018, 71, 102-111.	1.9	7
23	Vascular Access Outcomes Reported in Maintenance Hemodialysis Trials: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2018, 71, 382-391.	1.9	41
24	Su0008STANDARDISED OUTCOMES IN NEPHROLOGY (SONG): ESTABLISHING A CORE VASCULAR ACCESS OUTCOME MEASURE FOR TRIALS IN HAEMODIALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i619-i619.	0.7	0
25	Response to article by Caponi et al. about serum free light chains. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 57, e1-e2.	2.3	8
26	FP55EFFECTS OF FISH OIL SUPPLEMENTATION AND ASPIRIN USE ON NEED FOR ARTERIOVENOUS FISTULA INTERVENTIONS AND CENTRAL VENOUS CATHETERS IN PATIENTS REQUIRING HAEMODIALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i227-i227.	0.7	2
27	The Relationship between Body Mass Index and Organism-Specific Peritonitis. <i>Peritoneal Dialysis International</i> , 2018, 38, 206-214.	2.3	9
28	FP628A CORE OUTCOME SET FOR TRIALS IN HAEMODIALYSIS ESTABLISHED BY THE STANDARDISED OUTCOMES IN NEPHROLOGY - HAEMODIALYSIS INITIATIVE. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i255-i255.	0.7	0
29	Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in REnal Disease (FAVOURED) study. <i>Nephrology</i> , 2017, 22, 823-824.	1.6	3
30	Association between serum hepcidinâ€“25 and primary resistance to erythropoiesisâ€“stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. <i>Nephrology</i> , 2017, 22, 548-554.	1.6	11
31	A Trial of Extending Hemodialysis Hours and Quality of Life. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1898-1911.	6.1	62
32	Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. <i>American Journal of Kidney Diseases</i> , 2017, 70, 464-475.	1.9	218
33	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. <i>The Cochrane Library</i> , 2017, 2, CD009966.	2.8	20
34	Association of Socio-Economic Position with Technique Failure and Mortality in Australian Non-Indigenous Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2017, 37, 397-406.	2.3	14
35	Parathyroid hormone targets in chronic kidney disease and managing severe hyperparathyroidism. <i>Nephrology</i> , 2017, 22, 47-50.	1.6	11
36	Association between Peritoneal Glucose Exposure and Peritonitis in Peritoneal Dialysis Patients: TheBaLANZ Trial. <i>Peritoneal Dialysis International</i> , 2017, 37, 407-413.	2.3	6

#	ARTICLE	IF	CITATIONS
37	Endovascular Proximal Forearm Arteriovenous Fistula for Hemodialysis Access: Results of the Prospective, Multicenter Novel Endovascular Access Trial (NEAT). <i>American Journal of Kidney Diseases</i> , 2017, 70, 486-497.	1.9	115
38	Early and Late Patient Outcomes in Urgent-Start Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2017, 37, 414-419.	2.3	73
39	Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The <i>bal</i> ANZ Trial. <i>Peritoneal Dialysis International</i> , 2017, 37, 283-289.	2.3	40
40	Representativeness of Honeypot Trial Participants to Australasian PD Patients. <i>Peritoneal Dialysis International</i> , 2017, 37, 516-522.	2.3	3
41	Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis. <i>JAMA Internal Medicine</i> , 2017, 177, 184.	5.1	77
42	Outcomes of <i>Corynebacterium</i> Peritonitis: A Multicenter Registry Analysis. <i>Peritoneal Dialysis International</i> , 2017, 37, 619-626.	2.3	18
43	Sirolimus Increases T-Cell Abundance in the Sun Exposed Skin of Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2017, 3, e171.	1.6	5
44	Multicenter Registry Analysis of Center Characteristics Associated with Technique Failure in Patients on Incident Peritoneal Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1090-1099.	4.5	94
45	Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrology Hemodialysis (SONG-HD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2017, 69, 97-107.	1.9	148
46	Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial. <i>Kidney and Blood Pressure Research</i> , 2017, 42, 1033-1044.	2.0	7
47	The SIESTA Trial: A Randomized Study Investigating the Efficacy, Safety, and Tolerability of Acupressure versus Sham Therapy for Improving Sleep Quality in Patients with End-Stage Kidney Disease on Hemodialysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-10.	1.2	14
48	Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD. <i>BMC Nephrology</i> , 2017, 18, 281.	1.8	25
49	Factors associated with acutely elevated serum creatinine following radical tumour nephrectomy: the Correlates of Kidney Dysfunction Tumour Nephrectomy Database study. <i>Translational Andrology and Urology</i> , 2017, 6, 899-909.	1.4	4
50	Focus on peritoneal dialysis training: working to decrease peritonitis rates. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, gfu403.	0.7	40
51	Association between left ventricular global longitudinal strain, health-related quality of life and functional capacity in chronic kidney disease patients with preserved ejection fraction. <i>Nephrology</i> , 2016, 21, 108-115.	1.6	12
52	Baseline characteristics of the omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study. <i>Nephrology</i> , 2016, 21, 217-228.	1.6	10
53	Live donor study implications of kidney donation on cardiovascular risk with a focus on lipid parameters including lipoprotein a. <i>Nephrology</i> , 2016, 21, 901-904.	1.6	6
54	Prevalence of Skin Cancer and Related Skin Tumors in High-Risk Kidney and Liver Transplant Recipients in Queensland, Australia. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1382-1386.	0.7	41

#	ARTICLE	IF	CITATIONS
55	Predictors of Transfer to Home Hemodialysis after Peritoneal Dialysis Completion. <i>Peritoneal Dialysis International</i> , 2016, 36, 547-554.	2.3	16
56	Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. <i>Kidney International</i> , 2016, 89, 1337-1345.	5.2	44
57	The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2016, 68, 554-563.	1.9	51
58	Center-Specific Factors Associated with Peritonitis Risk—A Multi-Center Registry Analysis. <i>Peritoneal Dialysis International</i> , 2016, 36, 509-518.	2.3	54
59	The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. <i>Redox Report</i> , 2016, 21, 14-23.	4.5	8
60	Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1845-1855.	4.5	30
61	An update on bone imaging and markers in chronic kidney disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 455-466.	2.4	0
62	Association of anthropometric measures with kidney disease progression and mortality: a retrospective cohort study of pre-dialysis chronic kidney disease patients referred to a specialist renal service. <i>BMC Nephrology</i> , 2016, 17, 74.	1.8	15
63	Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multicentre registry study. <i>Nephrology</i> , 2016, 21, 387-396.	1.6	8
64	The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2016, 68, 591-598.	1.9	74
65	Intensive Hemodialysis and Mortality Risk in Australian and New Zealand Populations. <i>American Journal of Kidney Diseases</i> , 2016, 67, 617-628.	1.9	42
66	Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1425-1436.	0.7	34
67	Biological variation of high sensitivity cardiac troponin-T in stable dialysis patients: implications for clinical practice. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, e149-50.	2.3	0
68	Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions. <i>Peritoneal Dialysis International</i> , 2016, 36, 146-153.	2.3	3
69	Comparison of Freelite [®] and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1045-52.	2.3	16
70	The β -Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2016, 67, 902-911.	1.9	36
71	Higher Dialysate Matrix Metalloproteinase-2 Levels are Associated with Peritoneal Membrane Dysfunction. <i>Peritoneal Dialysis International</i> , 2016, 36, 16-25.	2.3	8
72	Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. <i>Internal Medicine Journal</i> , 2015, 45, 1054-1065.	0.8	25

#	ARTICLE	IF	CITATIONS
73	End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases. <i>American Journal of Nephrology</i> , 2015, 42, 177-184.	3.1	26
74	Standardised outcomes in nephrology " Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. <i>Trials</i> , 2015, 16, 364.	1.6	67
75	Left Ventricular Global Longitudinal Strain (GLS) Is a Superior Predictor of All-Cause and Cardiovascular Mortality When Compared to Ejection Fraction in Advanced Chronic Kidney Disease. <i>PLoS ONE</i> , 2015, 10, e0127044.	2.5	101
76	The impact of fibroblast growth factor-23 on the cardiovascular system in chronic kidney disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 565-568.	2.4	2
77	FP558OUTCOMES OF INTEGRATED HOME DIALYSIS CARE: A MULTI-CENTRE REGISTRY STUDY. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii260-iii260.	0.7	0
78	Biological variation of high sensitivity cardiac troponin-T in stable dialysis patients: implications for clinical practice. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 715-22.	2.3	27
79	The Role of Monitoring Vancomycin Levels in Patients with Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2015, 35, 222-228.	2.3	19
80	Baseline Serum Interleukin-6 Predicts Cardiovascular Events in Incident Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2015, 35, 35-42.	2.3	23
81	An Incident Cohort Study Comparing Survival on Home Hemodialysis and Peritoneal Dialysis (Australia) Tj ETQq1 1 0.784314 rgBT /Ow Nephrology: <i>CJASN</i> , 2015, 10, 1397-1407.	4.5	50
82	Research Priorities in CKD: Report of a National Workshop Conducted in Australia. <i>American Journal of Kidney Diseases</i> , 2015, 66, 212-222.	1.9	73
83	N-Terminal Pro" B-Type Natriuretic Peptide Variability in Stable Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 620-629.	4.5	29
84	Association between Serum Alkaline Phosphatase and Primary Resistance to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: A Secondary Analysis of the HERO Trial. <i>Canadian Journal of Kidney Health and Disease</i> , 2015, 2, 66.	1.1	8
85	The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUTcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. <i>BMC Nephrology</i> , 2015, 16, 89.	1.8	21
86	Left ventricular global longitudinal strain is associated with cardiovascular risk factors and arterial stiffness in chronic kidney disease. <i>BMC Nephrology</i> , 2015, 16, 106.	1.8	28
87	Outcomes of integrated home dialysis care: a multi-centre, multi-national registry study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1897-1904.	0.7	20
88	Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1774-1779.	0.7	13
89	Temporal Changes in Mortality Risk by Dialysis Modality in the Australian and New Zealand Dialysis Population. <i>American Journal of Kidney Diseases</i> , 2015, 66, 489-498.	1.9	41
90	Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The BAL Anz Trial. <i>Peritoneal Dialysis International</i> , 2015, 35, 159-171.	2.3	7

#	ARTICLE	IF	CITATIONS
91	Socio-Economic Status and Peritonitis in Australian Non-Indigenous Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2015, 35, 450-459.	2.3	16
92	The Effect of Exit-Site Antibacterial Honey versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial. <i>Peritoneal Dialysis International</i> , 2015, 35, 712-721.	2.3	14
93	The rationale and design of the <i>BLOCKER</i> to <i>LOWER</i> <i>CARDIOVASCULAR DIALYSIS EVENTS</i> (<i>BLOCKADE</i>) <i>Feasibility Study</i> . <i>Nephrology</i> , 2015, 20, 140-147.	1.6	6
94	A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial. <i>American Journal of Kidney Diseases</i> , 2015, 65, 49-57.	1.9	29
95	The Association between Body Mass Index and Mortality in Incident Dialysis Patients. <i>PLoS ONE</i> , 2014, 9, e114897.	2.5	37
96	End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2277-2286.	0.7	40
97	Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network. <i>Kidney International</i> , 2014, 85, 23-30.	5.2	17
98	Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 406-413.	0.7	191
99	The Role of Monitoring Gentamicin Levels in Patients with Gram-Negative Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2014, 34, 219-226.	2.3	14
100	Clinical Causes of Inflammation in Peritoneal Dialysis Patients. <i>International Journal of Nephrology</i> , 2014, 2014, 1-9.	1.3	34
101	An unusual case of severe acute tubular necrosis. <i>Nephrology</i> , 2014, 19, 62-63.	1.6	0
102	Atypical HUS associated with severe, unexpected antibody-mediated rejection post kidney transplant. <i>Nephrology</i> , 2014, 19, 22-26.	1.6	8
103	Buttonhole Cannulation and Clinical Outcomes in a Home Hemodialysis Cohort and Systematic Review. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 110-119.	4.5	93
104	Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1940-1947.	0.7	34
105	Uraemic toxins and cardiovascular disease across the chronic kidney disease spectrum: An observational study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 1035-1042.	2.6	34
106	Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 23-30.	9.1	76
107	Protein-bound Uremic Toxins, Inflammation and Oxidative Stress: A Cross-sectional Study in Stage 3-4 Chronic Kidney Disease. <i>Archives of Medical Research</i> , 2014, 45, 309-317.	3.3	137
108	Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients. <i>BMC Nephrology</i> , 2014, 15, 8.	1.8	46

#	ARTICLE	IF	CITATIONS
109	Effect of Hemodiafiltration or Hemofiltration Compared With Hemodialysis on Mortality and Cardiovascular Disease in Chronic Kidney Failure: A Systematic Review and Meta-analysis of Randomized Trials. <i>American Journal of Kidney Diseases</i> , 2014, 63, 968-978.	1.9	105
110	The association between left ventricular global longitudinal strain, renal impairment and all-cause mortality. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1218-1225.	0.7	56
111	A randomized trial of sodium-restriction on kidney function, fluid volume and adipokines in CKD patients. <i>BMC Nephrology</i> , 2014, 15, 57.	1.8	44
112	Uremic Toxin Development in Living Kidney Donors. <i>Transplantation</i> , 2014, 97, 548-554.	1.0	20
113	Corrigendum for NEP 1662. <i>Nephrology</i> , 2013, 18, 481-481.	1.6	1
114	Interventions for erythropoietin-resistant anaemia in dialysis patients. <i>The Cochrane Library</i> , 2013, , CD006861.	2.8	6
115	Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3-4: A randomized controlled trial. <i>Nephrology</i> , 2013, 18, 26-35.	1.6	25
116	Outcomes of Extended-Hours Hemodialysis Performed Predominantly at Home. <i>American Journal of Kidney Diseases</i> , 2013, 61, 247-253.	1.9	52
117	Is Alpha-B Crystallin an Independent Marker for Prognosis in Lung Cancer?. <i>Heart Lung and Circulation</i> , 2013, 22, 759-766.	0.4	11
118	Daily Variation in Death in Patients Treated by Long-term Dialysis: Comparison of In-Center Hemodialysis to Peritoneal and Home Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2013, 61, 96-103.	1.9	48
119	Renal services disaster planning: Lessons learnt from the 2011 Queensland floods and North Queensland cyclone experiences. <i>Nephrology</i> , 2013, 18, 41-46.	1.6	24
120	The Outcomes of Patients with ESRD and ANCA-Associated Vasculitis in Australia and New Zealand. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 773-780.	4.5	43
121	Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. <i>Kidney International</i> , 2013, 83, 503-510.	5.2	59
122	A Randomized Trial of Dietary Sodium Restriction in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 2096-2103.	6.1	253
123	Association of Biocompatible Peritoneal Dialysis Solutions with Peritonitis Risk, Treatment, and Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1556-1563.	4.5	26
124	The HoneyPot Randomized Controlled Trial Statistical Analysis Plan. <i>Peritoneal Dialysis International</i> , 2013, 33, 426-435.	2.3	9
125	Estimated GFR Reporting Influences Recommendations for Dialysis Initiation. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1737-1742.	6.1	6
126	Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 146-152.	0.7	64

#	ARTICLE	IF	CITATIONS
127	Effects of Climatic Region on Peritonitis Risk, Microbiology, Treatment, and Outcomes: A Multicenter Registry Study. <i>Peritoneal Dialysis International</i> , 2013, 33, 75-85.	2.3	17
128	Cardiac surgical outcomes in abdominal solid organ (renal and hepatic) transplant recipients: a case-matched study. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2013, 16, 103-111.	1.1	15
129	End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 455-461.	0.7	37
130	Treatment outcomes for ischemic heart disease in dialysis-dependent patients. <i>Asian Cardiovascular and Thoracic Annals</i> , 2012, 20, 281-291.	0.5	13
131	Biocompatible Peritoneal Dialysis Fluids: Clinical Outcomes. <i>International Journal of Nephrology</i> , 2012, 2012, 1-9.	1.3	18
132	Recent Peritonitis Associates with Mortality among Patients Treated with Peritoneal Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1398-1405.	6.1	198
133	A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4146-4153.	0.7	24
134	Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 381-387.	0.7	38
135	Weekend Compared with Weekday Presentations of Peritoneal Dialysis-associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2012, 32, 516-524.	2.3	16
136	Multimodality vascular imaging in CKD: divergence of risk between measured parameters. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1004-1012.	0.7	13
137	Seasonal variation in peritoneal dialysis-associated peritonitis: a multi-centre registry study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2028-2036.	0.7	31
138	A Randomized Controlled Trial of Intravenous or Oral Iron for Posttransplant Anemia in Kidney Transplantation. <i>Transplantation</i> , 2012, 93, 822-826.	1.0	33
139	Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week. <i>Transplant International</i> , 2012, 25, 1182-1193.	1.6	35
140	Australian consumer perspectives on dialysis: First national census. <i>Nephrology</i> , 2012, 17, 703-709.	1.6	22
141	Challenges in Blood Pressure Measurement in Patients Treated With Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2012, 60, 463-472.	1.9	13
142	The effect of lowering salt intake on ambulatory blood pressure to reduce cardiovascular risk in chronic kidney disease (LowSALT CKD study): protocol of a randomized trial. <i>BMC Nephrology</i> , 2012, 13, 137.	1.8	17
143	A randomised controlled trial of Heparin versus EthAnol Lock TherapY for the prevention of Catheter Associated infection in Haemodialysis patients - the HEALTHY-CATH trial. <i>BMC Nephrology</i> , 2012, 13, 146.	1.8	54
144	End-stage kidney disease due to haemolytic uraemic syndrome - outcomes in 241 consecutive ANZDATA registry cases. <i>BMC Nephrology</i> , 2012, 13, 164.	1.8	7

#	ARTICLE	IF	CITATIONS
145	The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study. <i>BMC Nephrology</i> , 2012, 13, 41.	1.8	27
146	Predictors of Vitamin D Status in Predialysis Chronic Kidney Disease Patients: A Cross-sectional Analysis in a High Ultraviolet Climate. , 2012, 22, 400-408.		11
147	Changes in serum prolactin, sex hormones and thyroid function with alternate nightly nocturnal home haemodialysis. <i>Nephrology</i> , 2012, 17, 42-47.	1.6	42
148	A limited sampling strategy for the simultaneous estimation of tacrolimus, mycophenolic acid and unbound prednisolone exposure in adult kidney transplant recipients. <i>Nephrology</i> , 2012, 17, 294-299.	1.6	16
149	Repeated Peritoneal Dialysisâ€Associated Peritonitis: A Multicenter Registry Study. <i>American Journal of Kidney Diseases</i> , 2012, 59, 84-91.	1.9	19
150	Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk. <i>Nephrology</i> , 2012, 17, 433-444.	1.6	42
151	Effects of Beta-Adrenergic Antagonists in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1152-1161.	2.8	148
152	How Australian nephrologists view home dialysis: Results of a national survey. <i>Nephrology</i> , 2011, 16, 446-452.	1.6	62
153	Is the problem with the vehicle or the destination? Does highâ€dose ESA or high haemoglobin contribute to poor outcomes in CKD?. <i>Nephrology</i> , 2011, 16, 144-153.	1.6	11
154	Home Hemodialysis in Australia and New Zealand: How and Why it has been Successful. <i>Seminars in Dialysis</i> , 2011, 24, 658-663.	1.3	21
155	Alternate Night Nocturnal Hemodialysis: The Australian Experience. <i>Seminars in Dialysis</i> , 2011, 24, 664-667.	1.3	13
156	International quotidian dialysis registry: Annual report 2010. <i>Hemodialysis International</i> , 2011, 15, 15-22.	0.9	16
157	Relapsing and Recurrent Peritoneal Dialysisâ€Associated Peritonitis: A Multicenter Registry Study. <i>American Journal of Kidney Diseases</i> , 2011, 58, 429-436.	1.9	63
158	Home Hemodialysis and Mortality Risk in Australian and New Zealand Populations. <i>American Journal of Kidney Diseases</i> , 2011, 58, 782-793.	1.9	168
159	Evaluation of limited sampling strategies for total and free prednisolone in adult kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 1243-1252.	1.9	16
160	Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?. <i>BMC Nephrology</i> , 2011, 12, 20.	1.8	42
161	Cardiac and vascular structure and function parameters do not improve with alternate nightly home hemodialysis: An interventional cohort study. <i>BMC Nephrology</i> , 2011, 12, 51.	1.8	10
162	Cardiorespiratory Fitness Is Independently Associated with 25-Hydroxyvitamin D in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 512-518.	4.5	15

#	ARTICLE	IF	CITATIONS
163	Challenges of conducting a trial of uric-acid-lowering therapy in CKD. <i>Nature Reviews Nephrology</i> , 2011, 7, 295-300.	9.6	46
164	End-stage kidney disease due to scleroderma—outcomes in 127 consecutive ANZDATA registry cases. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3165-3171.	0.7	33
165	Effect of Dialysis Modality on Survival of Hepatitis C-Infected ESRF Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2657-2661.	4.5	6
166	Polymicrobial Peritonitis in Peritoneal Dialysis Patients in Australia: Predictors, Treatment, and Outcomes. <i>American Journal of Kidney Diseases</i> , 2010, 55, 121-131.	1.9	80
167	Culture-Negative Peritonitis in Peritoneal Dialysis Patients in Australia: Predictors, Treatment, and Outcomes in 435 Cases. <i>American Journal of Kidney Diseases</i> , 2010, 55, 690-697.	1.9	85
168	Quality of life and alternate nightly nocturnal home hemodialysis. <i>Hemodialysis International</i> , 2010, 14, 29-38.	0.9	39
169	The impact of extended 8-hour home hemodialysis and buttonhole cannulation technique on hospitalization rates for septic events related to dialysis access. <i>Hemodialysis International</i> , 2010, 14, 451-463.	0.9	61
170	Clinical research for nephrologists: a practical series. <i>Nephrology</i> , 2010, 15, 7-7.	1.6	0
171	Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. <i>Nephrology</i> , 2010, 15, 714-719.	1.6	4
172	Staphylococcus Aureus Peritonitis in Australian Peritoneal Dialysis Patients: Predictors, Treatment, and Outcomes in 503 Cases. <i>Peritoneal Dialysis International</i> , 2010, 30, 311-319.	2.3	84
173	Enterococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 116 cases. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1272-1278.	0.7	70
174	Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1973-1979.	0.7	84
175	Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. <i>Kidney International</i> , 2010, 77, 904-912.	5.2	154
176	Coagulase-negative staphylococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 936 cases. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3386-3392.	0.7	60
177	Probable tacrolimus toxicity from tibolone co-administration in a woman: a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 276.	0.8	3
178	Predictors, treatment, and outcomes of non-Pseudomonas Gram-negative peritonitis. <i>Kidney International</i> , 2010, 78, 408-414.	5.2	62
179	Pseudomonas Peritonitis in Australia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 957-964.	4.5	92
180	Association of Dialysis Modality and Cardiovascular Mortality in Incident Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1620-1628.	4.5	85

#	ARTICLE	IF	CITATIONS
181	Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. <i>Kidney International</i> , 2009, 76, 622-628.	5.2	134
182	<i>Corynebacterium</i> peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3834-3839.	0.7	46
183	Recovery of renal function in end-stage renal failure--comparison between peritoneal dialysis and haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2825-2831.	0.7	31
184	Life-threatening adenovirus infection in a kidney transplant recipient. <i>CKJ: Clinical Kidney Journal</i> , 2009, 2, 250-253.	2.9	10
185	Adherence to guideline recommendations for infection prophylaxis in peritoneal dialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2009, 2, 508-508.	2.9	8
186	Associations of Dialysis Modality and Infectious Mortality in Incident Dialysis Patients in Australia and New Zealand. <i>American Journal of Kidney Diseases</i> , 2009, 53, 290-297.	1.9	112
187	Patients' Experiences and Perspectives of Living With CKD. <i>American Journal of Kidney Diseases</i> , 2009, 53, 689-700.	1.9	162
188	Intradermal Versus Intramuscular Hepatitis B Vaccination in Hemodialysis Patients: A Prospective Open-Label Randomized Controlled Trial in Nonresponders to Primary Vaccination. <i>American Journal of Kidney Diseases</i> , 2009, 54, 95-103.	1.9	63
189	In Reply to "Intramuscular or Intradermal Hepatitis B Vaccine Administration in Hemodialysis Patients". <i>American Journal of Kidney Diseases</i> , 2009, 54, 982.	1.9	2
190	Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access Outcomes in REnal Disease (FAVOURED) study. <i>BMC Nephrology</i> , 2009, 10, 1.	1.8	58
191	Intravenous versus oral iron supplementation for correction of post-transplant anaemia in renal transplant patients. <i>BMC Nephrology</i> , 2009, 10, 14.	1.8	11
192	Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases. <i>BMC Nephrology</i> , 2009, 10, 19.	1.8	52
193	Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT) Tj ETQq1 1 0.744314 rgBT /Overl	1.8	17
194	Rationale and design of the HEALTHY-CATH trial: A randomised controlled trial of Heparin versus EthAnol Lock TherapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. <i>BMC Nephrology</i> , 2009, 10, 23.	1.8	17
195	Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. <i>BMC Nephrology</i> , 2009, 10, 29.	1.8	16
196	The role of 25-hydroxyvitamin D deficiency in promoting insulin resistance and inflammation in patients with Chronic Kidney Disease: a randomised controlled trial. <i>BMC Nephrology</i> , 2009, 10, 41.	1.8	25
197	International quotidian dialysis registry: Annual report 2009. <i>Hemodialysis International</i> , 2009, 13, 240-249.	0.9	19
198	Prevention of access-related infection in dialysis. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 1185-1200.	4.4	24

#	ARTICLE	IF	CITATIONS
199	Predicting Risk of Nonmelanoma Skin Cancer and Premalignant Skin Lesions in Renal Transplant Recipients. <i>Transplantation</i> , 2009, 87, 1667-1671.	1.0	54
200	Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. <i>BMC Nephrology</i> , 2008, 9, 8.	1.8	17
201	Post-transplant hepatosplenic T-cell lymphoma successfully treated with hyperCVAD regimen. <i>American Journal of Hematology</i> , 2008, 83, 330-333.	4.1	27
202	Complications of home hemodialysis. <i>Hemodialysis International</i> , 2008, 12, S21-S25.	0.9	20
203	Review Article: Is it time to embrace haemodiafiltration for centre-based haemodialysis? (Review) <i>TJ ETQq1 1 0.784314 rgBT /QOverlock</i>	1.6	9
204	Change in live donor characteristics over the last 25 years: A single centre experience. <i>Nephrology</i> , 2008, 13, 646-650.	1.6	9
205	Kidneys from patients with small renal tumours: a novel source of kidneys for transplantation. <i>BJU International</i> , 2008, 102, 188-193.	2.5	71
206	Cutaneous manifestations of cytomegalovirus disease in renal transplant recipients: a case series. <i>Transplant Infectious Disease</i> , 2008, 10, 209-213.	1.7	36
207	Automated and continuous ambulatory peritoneal dialysis have similar outcomes. <i>Kidney International</i> , 2008, 73, 480-488.	5.2	68
208	The impact of automated eGFR reporting and education on nephrology service referrals. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3845-3850.	0.7	68
209	Patients' priorities for health research: focus group study of patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3206-3214.	0.7	124
210	Estimated donor glomerular filtration rate is the most important donor characteristic predicting graft function in recipients of kidneys from live donors. <i>Transplant International</i> , 2007, 20, 64-72.	1.6	29
211	Baseline and time-averaged fluid removal affect technique survival in peritoneal dialysis in a non-linear fashion. <i>Nephrology</i> , 2007, 12, 218-223.	1.6	7
212	Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysis. <i>Nephrology</i> , 2007, 12, 224-233.	1.6	35
213	Is it time to revisit residual renal function in haemodialysis? (Review Article). <i>Nephrology</i> , 2007, 12, 209-217.	1.6	15
214	Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. <i>Nephrology</i> , 2007, 12, 391-398.	1.6	102
215	A Randomized Controlled Trial of Coiled Versus Straight Swan-Neck Tenckhoff Catheters in Peritoneal Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2006, 48, 812-821.	1.9	71
216	Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. <i>American Heart Journal</i> , 2006, 151, 745-753.	2.7	67

#	ARTICLE	IF	CITATIONS
217	Biochemical Targets. <i>Nephrology</i> , 2006, 11, S198-S229.	1.6	2
218	Management of Bone Disease, Calcium, Phosphate and Parathyroid Hormone. <i>Nephrology</i> , 2006, 11, S230-61.	1.6	34
219	A Randomized Controlled Trial of Fludrocortisone for the Treatment of Hyperkalemia in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2006, 47, 809-814.	1.9	30
220	Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 776-783.	0.7	41
221	Deceased donor renal transplantation—does side matter?. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2583-2588.	0.7	15
222	Should an Oral Glucose Tolerance Test Be Performed Routinely in All Renal Transplant Recipients?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 100-108.	4.5	48
223	Does Uric Acid Have a Pathogenetic Role in Graft Dysfunction and Hypertension in Renal Transplant Recipients?. <i>Transplantation</i> , 2005, 80, 1565-1571.	1.0	53
224	Free Fatty Acids Are Associated with Obesity, Insulin Resistance, and Atherosclerosis in Renal Transplant Recipients. <i>Transplantation</i> , 2005, 80, 937-944.	1.0	39
225	Elevated white cell count at commencement of peritoneal dialysis predicts overall and cardiac mortality. <i>Kidney International</i> , 2005, 67, 738-743.	5.2	37
226	Impact of obesity on renal transplant outcomes. <i>Nephrology</i> , 2005, 10, 405-413.	1.6	78
227	Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 271-280.	2.4	97
228	Obesity is Associated with Worsening Cardiovascular Risk Factor Profiles and Proteinuria Progression in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 2710-2718.	4.7	107
229	Generalized, pruritic, ulcerating maculopapular rash necessitating cessation of sirolimus in a liver transplantation patient. <i>Liver Transplantation</i> , 2005, 11, 987-989.	2.4	15
230	Randomized, Controlled Trial of Topical Exit-Site Application of Honey (Medihoney) versus Mupirocin for the Prevention of Catheter-Associated Infections in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1456-1462.	6.1	135
231	Incremental Value of Strain Rate Analysis as an Adjunct to Wall-Motion Scoring for Assessment of Myocardial Viability by Dobutamine Echocardiography. <i>Circulation</i> , 2005, 112, 3892-3900.	1.6	159
232	Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2178-2185.	0.7	11
233	Polymorphisms in glutathione S-transferases and non-melanoma skin cancer risk in Australian renal transplant recipients. <i>Carcinogenesis</i> , 2004, 26, 185-191.	2.8	45
234	Effects of Early and Late Intervention with Epoetin $\hat{\pm}$ on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4). <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 148-156.	6.1	206

#	ARTICLE	IF	CITATIONS
235	Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. <i>Nephrology</i> , 2004, 9, 406-413.	1.6	18
236	The effect of oral iron administration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. <i>Transplantation</i> , 2004, 77, 206-209.	1.0	40
237	Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: A prospective study in Queensland, Australia. <i>American Journal of Kidney Diseases</i> , 2003, 41, 676-683.	1.9	122
238	Durable and high rates of remission following chemotherapy in posttransplantation lymphoproliferative disorders after renal transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 256-257.	0.6	9
239	Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 397-406.	1.2	105
240	Frequency and severity of acute rejection in live- versus cadaveric-donor renal transplants. <i>Transplantation</i> , 2003, 76, 1452-1457.	1.0	38
241	BODY MASS INDEX AND RENAL TRANSPLANT OUTCOMES. <i>Transplantation</i> , 2003, 76, 1651.	1.0	0
242	A randomized controlled trial of topical exit site mupirocin application in patients with tunneled, cuffed haemodialysis catheters. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1802-1807.	0.7	148
243	The effect of obesity on renal transplant outcomes. <i>Transplantation</i> , 2002, 74, 675-681.	1.0	217
244	Neutrophil dysplasia characterised by a pseudo-Pelger-Huet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases. <i>Pathology</i> , 2002, 34, 263-266.	0.6	33
245	Non-melanoma skin cancer risk in the Queensland renal transplant population. <i>British Journal of Dermatology</i> , 2002, 147, 950-956.	1.5	263
246	Severe hypokalaemia secondary to dicloxacillin. <i>Internal Medicine Journal</i> , 2002, 32, 357-358.	0.8	13
247	Role of cytokine gene polymorphisms in acute rejection and renal impairment after liver transplantation. <i>Liver Transplantation</i> , 2001, 7, 255-263.	2.4	28
248	Polymorphisms of the renin-angiotensin system in patients with multifocal renal arterial fibromuscular dysplasia. <i>Journal of Human Hypertension</i> , 2001, 15, 185-190.	2.2	48
249	Is C-Reactive Protein a Useful Predictor of Outcome in Peritoneal Dialysis Patients?. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 814-821.	6.1	111
250	A COMPARISON OF THE EFFECTS OF DIALYSIS AND RENAL TRANSPLANTATION ON THE SURVIVAL OF OLDER UREMIC PATIENTS. <i>Transplantation</i> , 2000, 69, 794-799.	1.0	138
251	A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients. <i>Clinical Transplantation</i> , 1999, 13, 520-525.	1.6	22
252	Transitional cell carcinoma in renal transplant recipients: the influence of compound analgesics. <i>British Journal of Urology</i> , 1998, 81, 229-233.	0.1	37

#	ARTICLE	IF	CITATIONS
253	Sclerosing peritonitis: the experience in Australia. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 154-159.	0.7	300
254	ADVANCED DONOR-ORIGIN MELANOMA IN A RENAL TRANSPLANT RECIPIENT. <i>Transplantation</i> , 1998, 66, 655-661.	1.0	41
255	<i>Moraxella nonliquefaciens</i> Septic Arthritis in a Patient Undergoing Hemodialysis. <i>Clinical Infectious Diseases</i> , 1995, 21, 1039-1040.	5.8	17
256	Recovery of gastrointestinal function after renal transplantation in a patient with sclerosing peritonitis secondary to continuous ambulatory peritoneal dialysis. <i>American Journal of Kidney Diseases</i> , 1995, 26, 658-661.	1.9	55
257	Dramatic response of livedoid vasculitis to tissue plasminogen activator (tPA). <i>Australian and New Zealand Journal of Medicine</i> , 1995, 25, 370-371.	0.5	3
258	Sclerosing Peritonitis: Identification of Diagnostic, Clinical, and Radiological Features. <i>American Journal of Kidney Diseases</i> , 1994, 24, 819-825.	1.9	91
259	Onset of Dialysis Encephalopathy in Cyclosporine-Treated Renal Allograft Recipients. <i>American Journal of Kidney Diseases</i> , 1990, 15, 364-368.	1.9	6
260	Sodium depletion decreases hepatic metabolism of vasoactive intestinal peptide in the rabbit.. <i>Journal of Physiology</i> , 1989, 418, 251-259.	2.9	16
261	Hemodynamic properties of bucindolol, a beta-adrenoreceptor blocking drug with vasodilator activity. <i>American Journal of Cardiology</i> , 1986, 57, 678-681.	1.6	10
262	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. <i>The Cochrane Library</i> , 0, , .	2.8	5